FDA expands approved use of metastatic breast cancer treatment to include male patients - FDA Press Releases

The FDA is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

from Food and Drug Administration--Press Releases https://ift.tt/2FW0x18
via IFTTT